Global Cervical Dysplasia Market: Snapshot
Cervical dysplasia is one of the fastest growing market in the field of cancer diagnosis and treatment. Cervical cancer is a precancerous stage and it can be completely cured by early detection. Rising consumer awareness in this regard has led to an increased demand for cervical screenings in the past few years. Government bodies in several developed countries conduct screening programs in order to improve the quality of life of population by reducing the mortality rate. Furthermore, recommendations from government organization for early detection of chronic diseases including cervical dysplasia is one of the major factors that is expected to drive the overall cervical dysplasia market over the forecast period.
Transparency Market Research states that the global cervical dysplasia market was valued at US$349.0 mn in 2015 and will expand at a CAGR of 7.0 % during the period between 2016 and 2024, to reach US$ 640.2 mn by 2024.
Thanks to High Accuracy and Low Cost, HPV Tests to See Vast Rise in Demand
Based on diagnosis, the market has been segmented into diagnostic tests and diagnostic devices. Furthermore, the diagnosis test segment is examined for Pap smear (Papanicolaou) test, HPV (human papillomavirus) test, and biopsy. Colposcope devices are considered as diagnostic devices for cervical dysplasia market in this report. Of these, the segment of diagnostic tests accounted for around 86.3% of the market in terms of revenue in 2015. Availability of reimbursement for cervical dysplasia screening tests in mature markets such as North America and Europe is one of the key factors expected to fuel the sales of cervical dysplasia diagnostic tests market in the next few years.
Of the key cervical dysplasia diagnostic tests analyzed in the report, the segment of HPV tests is expected to grow at a higher CAGR over the forecast period owing to the rising aversion to Pap smear tests and advancements in HPV testing technologies. The significant false-negative rate and high costs of Pap smear tests have resulted in a vast decline in their demand, with the more accurate and cost-effective HPV testing emerging as one of the primary screening tool recommended by healthcare providers these days.
Developed Economies to Continue Being Most Lucrative
Geographically, North America was the dominant market for cervical dysplasia in 2015. The region accounted for a share of over 55.2% of the global cervical dysplasia market in the said year. Rising awareness about cervical dysplasia screening programs and technological advancements in screening devices and other supporting equipment are the key factors fueling the growth of the North America cervical dysplasia market. The diagnosis test segment in North America dominated, accounting for over 85% in the regional market in 2015. The increasing incidence rate of cervical cancer in women above the age of 50 years and favorable reimbursement policies supported by federal organizations such as Medicare are also expected to drive the market in North America in the next few years.
The cervical dysplasia market in Asia Pacific is anticipated to witness the most promising growth rate during the forecast period, chiefly owing to the improving healthcare infrastructure and encouraging government funding on cancer research in the region. The markets in emerging economies such as India and China are expected to exhibit significant expansion in the next few years. Several government-funded cervical dysplasia screening programs in these countries, initiated with the aim of reducing the mortality rate by improving the quality of life of the population will be a key driver of the market.
Some of the key players operating in the global cervical dysplasia market are F. Hoffmann La-Roche Ltd., QIAGEN, Becton, Dickinson and company, OncoHealth Corporation, Quest Diagnostics, Inc., Hologic, Inc., and Abbott Healthcare Pvt Ltd.
Global Cervical Dysplasia Market: Scope and Methodology
This report on the global cervical dysplasia market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global cervical dysplasia market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global cervical cancer market.
Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market size estimations involved in-depth study of services and product features of different types of services. Additionally, market related factors such as increasing preference for technologically advanced services, product innovation, and increasing prevalence of cancer and other chronic diseases in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
Cervical Dysplasia Market: Segmentation
Based on the diagnosis, the market has been further segmented into two major segments namely, diagnosis tests and diagnostic devices. Diagnosis segment further sub-segmented into Pap smear test, HPV test, and Biopsy. Moreover, colposcope devices are considered as diagnostic devices for cervical dysplasia market in this report. Based on end user, the market has been segmented into hospitals, diagnostic centers, private gynecological offices, research & academic institutes and ambulatory surgical centers.
Cervical Dysplasia Market: Geographical and Competitive Dynamics
Geographically, the global cervical dysplasia market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Japan, India, Saudi Arabia, UAE, Brazil, and Mexico.
The report also profiles major players in the cervical dysplasia market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include F. Hoffmann La-Roche Ltd., QIAGEN, Becton, Dickinson and company, OncoHealth Corporation, Quest Diagnostics, Inc., Hologic, Inc., and Abbott Healthcare Pvt Ltd, exhibit the largest geographical outreach with presence in cervical dysplasia product categories.
The global cervical dysplasia market is segmented as follows:
Global Cervical Dysplasia Market Revenue, by Diagnosis
- Diagnosis Test
- Pap Smear Test
- HPV Test
- Diagnostic Device
Global Cervical Dysplasia Market Revenue, by End User
- Diagnostic Centers
- Private Gynecologists’ Offices
- Research & Academic Institutes
- Ambulatory Surgical Centers
Global Cervical Dysplsia Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- Rest of Middle East & Africa